chromosone screening

Is Medicine a Big Data Problem?

By Ted Driscoll / March 21, 2014 / 0 Comments

Human beings are big data. We aren’t just 175 pounds of meat and bone. We aren’t just piles of hydrogen and carbon and oxygen. What makes us all different is how it’s all organized and that is information.
We can no longer treat people based on simple numbers like weight, pulse, blood pressure, and temperature. What makes us different is much more complicated than that.

Read More

Ted Driscoll’s WSJ interview: 23andMe Flap With FDA Just a Bump in the Road, One Genetics-Testing Investor Says

By Claremont Creek Alerts / December 16, 2013 / 0 Comments

source:   by Timothy Hay When the Food and Drug Administration told personal-genetics company 23andMe Inc. in November to stop sending consumers detailed information about their DNA, some industry watchers said the move could be a devastating blow to an emerging area of medicine that holds promise for better health outcomes. But it was more of […]

Read More

Assurex Health Publishes Seminal Paper on Pharmacogenomics

By Brad Webb / November 2, 2013 / 0 Comments

Our portfolio company Assurex Health, announced recently the publication of a groundbreaking analysis of pharmacogenomic data in the International Review of Psychiatry. The publication strongly validates the premise that the clinical use of genomic testing to help predict patient response to psychiatric medications significantly improves treatment outcomes. This is a key milestone in the continuing […]

Read More

NuMedii Founder Atul Butte, MD, PhD honored at White House; Claremont Creek Ventures continues investment in health care Big Data.

By Brad Webb / June 20, 2013 / 0 Comments

Thursday June 20, 2013, Atul Butte, MD, PhD, a Stanford University Professor and entrepreneur is being honored at a formal ceremony in the White House Rose Garden in Washington DC.  The Obama Administration is honoring Dr. Butte and several other genomics and molecular biology researchers who have focused on making large and complex sets of […]

Read More

Congratulations to Natera on Completing $54.6 Million Financing to Support Expansion

By Ted Driscoll / May 3, 2013 / 0 Comments

Congratulations to Claremont Creek portfolio company Natera on closing a $54.6 million financing round. Given Claremont Creek Venture’s involvement since the company’s earliest round of financing, we know Natera is on its way to dominating the market for noninvasive, prenatal genetic testing. The financing is just the latest recent milestone for the company. In February […]

Read More

Congratulations: Quest Diagnostics to offer access to Natera’s Panorama, non-invasive prenatal test

By Ted Driscoll / February 23, 2013 / 0 Comments

Congratulations to Natera—our portfolio company who is the leading innovator in prenatal genetic testing! Yesterday they announced a major deal with Quest Diagnostics (NYSE: DGX), the world’s leading diagnostic information services company. Quest Diagnostics will offer physicians access to Panorama™, the new non-invasive prenatal test developed by Natera. (Read the Quest Press Release) Panorama uses […]

Read More

Meet our team

Claremont Creek Ventures was founded in 2005 by Nat Goldhaber, John Steuart and Randy Hawks to pursue early stage investing in exceptional technology startups.

Nat_Boldhaber7718 -1200px

NAT GOLDHABER

Nat Goldhaber is a co-founder of Claremont Creek Ventures. 

TED DRISCOLL

Ted is an expert on digital health and diagnostics, from big data and health technology to genomics and personalized medicine.

Paul_Straub7765 -1200px

PAUL STRAUB

Paul is particularly focused on the potential of digital and business innovation to impact and advance broad-impact industries.

Brad_Webb8124 1200px crop

BRAD WEBB

Brad is focused on the role of genomics and biomarker data analytics in driving the next generation of diagnostics and drug development.

Randy_Hawks7690 -1200px

RANDY HAWKS

Randy Hawks is a co-founder of Claremont Creek Ventures.

Post Categories

Archives